Paul Matteis Analyst Performance

Managing Director, Head of Therapeutics Research Biotechnology at Stifel Nicolaus

Paul Matteis is a stock analyst at Stifel Nicolaus in the medical sector, covering 28 publicly traded companies. Over the past year, Paul Matteis has issued 11 stock ratings, including buy and hold recommendations. While full access to Paul Matteis' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Paul Matteis' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

91 Last 10 Years

Buy Recommendations

77.53% 69 Buy Ratings

Companies Covered

28 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	77.5%	69 ratings
Hold	22.5%	20 ratings
Sell	0.0%	0 ratings

Out of 89 total stock ratings issued by Paul Matteis at Stifel Nicolaus, the majority (77.5%) have been Buy recommendations, followed by 22.5% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  SAGE

  Jun 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  OREX

  May 2015

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	28 companies

Paul Matteis, an analyst at Stifel Nicolaus, currently covers 28 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 28 companies	100.0%

Paul Matteis of Stifel Nicolaus specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 14 companies	50.0%
PHARMACEUTICAL PREPARATIONS 7 companies	25.0%
MED - DRUGS 3 companies	10.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 2 companies	7.1%
MEDICAL SERVICES 1 company	3.6%
BIOTECHNOLOGY 1 company	3.6%

About Paul Matteis

Paul Matteis joined Stifel in 2018. Based out of the firm’s Boston office, he serves as a Managing Director and Head of Biotech Research. Previously, Paul was a Senior Biotechnology Analyst covering small-cap and mid-cap companies at Leerink, with a focus on neuroscience, central nervous system and rare disease. Before this, he was a Research Assistant at the Harvard Division of Sleep Medicine at Brigham & Women’s Hospital. Paul was named a “Runner Up” in Small/Mid Cap Biotechnology in 2019-2024, as well as a “Rising Star” by Institutional Investor in both 2015 and 2016, as part of the publication’s All-America Research Team rankings. He attended Skidmore College in New York, where he studied Psychology and Pre-Medical Sciences and graduated Phi Beta Kappa.

Follow on LinkedIn

Paul Matteis' Ratings History at Stifel Nicolaus

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
VRTX Vertex Pharmaceuticals	8/5/2025	Lower Price Target	$472.27	$455.00	Hold	$0.00 00.00% ROI
NBIX Neurocrine Biosciences	7/31/2025	Boost Price Target	$131.49	$174.00	Buy	$0.00 00.00% ROI
DYN Dyne Therapeutics	7/31/2025	Lower Price Target	$9.90	$36.00	Buy	$0.00 00.00% ROI
RYTM Rhythm Pharmaceuticals	5/29/2025	Boost Price Target	$62.66	$94.00	Buy	$0.00 00.00% ROI
VIGL Vigil Neuroscience	5/28/2025	Downgrade	$7.88	$8.00	Hold	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	3/31/2025	Boost Price Target	$268.46	$345.00	Buy	$0.00 00.00% ROI
NMRA Neumora Therapeutics	3/7/2025	Downgrade	$1.52	$2.00	Hold	$0.00 00.00% ROI
RYTM Rhythm Pharmaceuticals	3/5/2025	Initiated Coverage	$54.02	$78.00	Buy	$0.00 00.00% ROI
SION Sionna Therapeutics	3/4/2025	Initiated Coverage	$14.41	$32.00	Buy	$0.00 00.00% ROI
CMPS COMPASS Pathways	2/27/2025	Initiated Coverage	$3.70	$11.00	Buy	$0.00 00.00% ROI
GHRS GH Research	2/27/2025	Boost Price Target	$10.82	$32.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.